It’s been a crucial week for CVS Health Corporation (NYSE:CVS); here’s what analysts have to say.

March 19, 2018 - By Darrin Black

 It's been a crucial week for CVS Health Corporation (NYSE:CVS); here's what analysts have to say.
Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.04, from 0.92 in 2017Q2. It fall, as 60 investors sold CVS Health Corporation shares while 571 reduced holdings. 88 funds opened positions while 466 raised stakes. 801.45 million shares or 0.31% less from 803.96 million shares in 2017Q2 were reported.
Maple accumulated 91,770 shares. Salem Counselors Inc invested 0.64% in CVS Health Corporation (NYSE:CVS). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt Corp reported 121,500 shares stake. Argyle owns 25,010 shares for 0.8% of their portfolio. Wagner Bowman Management Corporation invested in 0.48% or 21,197 shares. Norinchukin Comml Bank The, a Japan-based fund reported 150,280 shares. Amer Assets Inv Management Ltd Llc stated it has 20,000 shares. 15,030 were reported by Iberiabank. Da Davidson holds 666,318 shares. Compton Management Ri reported 29,596 shares stake. Northern has invested 0.34% in CVS Health Corporation (NYSE:CVS). Bp Pcl holds 118,000 shares. Petrus Lta invested 3.86% of its portfolio in CVS Health Corporation (NYSE:CVS). Estabrook Mgmt holds 5,207 shares. Benjamin F Edwards & Inc holds 0.26% or 26,459 shares in its portfolio.

Since October 2, 2017, it had 0 insider purchases, and 2 insider sales for $3.09 million activity. Another trade for 20,547 shares valued at $1.67 million was sold by Moriarty Thomas M.

CVS Health Corporation (NYSE:CVS) Ratings Coverage

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health has $132 highest and $73 lowest target. $96.86’s average target is 52.85% above currents $63.37 stock price. CVS Health had 73 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of CVS Health Corporation (NYSE:CVS) has “Outperform” rating given on Friday, August 28 by Oppenheimer. Needham maintained CVS Health Corporation (NYSE:CVS) on Friday, September 8 with “Hold” rating. The stock has “Strong Buy” rating by S&P Research on Monday, November 2. The company was maintained on Friday, October 27 by Robert W. Baird. As per Wednesday, July 22, the company rating was maintained by Deutsche Bank. The rating was maintained by Deutsche Bank on Thursday, August 20 with “Hold”. JP Morgan maintained the stock with “Overweight” rating in Monday, November 2 report. The rating was downgraded by Wolfe Research on Wednesday, August 16 to “Hold”. The rating was maintained by Citigroup with “Neutral” on Tuesday, February 13. Robert W. Baird maintained the shares of CVS in report on Monday, September 25 with “Hold” rating. Below is a list of CVS Health Corporation (NYSE:CVS) latest ratings and price target changes.

27/02/2018 Broker: Bank of America Rating: Buy New Target: $91.0
13/02/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $80 New Target: $77 Maintain
09/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $90 New Target: $85 Maintain
08/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $89.0 Maintain
08/02/2018 Broker: Robert W. Baird Rating: Hold New Target: $80.0 Maintain
30/01/2018 Broker: Needham Rating: Buy Upgrade
24/01/2018 Broker: Mizuho Rating: Buy New Target: $95.0 Maintain
17/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $85.0 Maintain
08/01/2018 Broker: Leerink Swann Rating: Buy New Target: $90.0 Maintain
04/01/2018 Broker: SunTrust Rating: Buy New Target: $90.0 Maintain

The stock decreased 3.47% or $2.28 during the last trading session, reaching $63.37. About 6.74M shares traded. CVS Health Corporation (NYSE:CVS) has declined 24.40% since March 19, 2017 and is downtrending. It has underperformed by 41.10% the S&P500.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. The company has market cap of $64.35 billion. It operates through Pharmacy Services and Retail/LTC divisions. It has a 9.84 P/E ratio. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.